In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The company is developing an oral and a subcutaneous version of this medicine ... amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

More and more people are taking weight loss injectables like Wegovy and Mounjaro — and though the drugs are gaining credibility when used properly, pharmacy experts are worried that not everyone ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.